Paper Details

  1. Home
  2. Paper Details

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.

Author: , EminiEmilio A, FlodmarkCarl-Erik, GruberWilliam C, GurtmanAlejandra, RomboLars, ScottDaniel A, SidhuMohinder, SilfverdalSven Arne, TanseySusan P, TrammelJames

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study evaluated the immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) in infants and toddlers who previously received one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7). The study found PCV13 to be immunogenic and safe in these children.
Paper Details　
Original Abstract of the Article :
As 13-valent pneumococcal conjugate vaccine (PCV13) is introduced, children who began vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) may complete their vaccination with PCV13. This open-label phase 3 study evaluated immunogenicity and safety of PCV13 in Swedish infants and toddlers ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2012.12.066

データ提供：米国国立医学図書館（NLM）

PCV13: A New Oasis in the Desert of Pneumococcal Infections

Pneumococcal infections, like desert storms, can be unpredictable and dangerous, especially for young children. Vaccines are our primary defense against these infections, providing a protective shield against disease. This study explores the safety and effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in children who had previously received the 7-valent pneumococcal conjugate vaccine (PCV7).

The study involved Swedish infants and toddlers who had received one or two doses of PCV7. The researchers found that PCV13 was safe and effective, generating strong immune responses in these children. This suggests that PCV13 can be safely used to complete the vaccination series in children who have already received PCV7.

Building Immunity: A Protective Barrier Against Infection

This study provides valuable insights into the effectiveness of PCV13 in children who have already received PCV7. By boosting immunity, PCV13 can help protect children from the devastating effects of pneumococcal infections. This research reinforces the importance of vaccination in protecting children from disease and creating a healthier future for all.

A Safer Desert Journey: Navigating the World of Vaccines

The desert of childhood illnesses can be a dangerous place. Vaccines, like reliable oases, offer protection against a wide range of diseases. This study underscores the importance of vaccination and provides valuable information for completing the vaccination series in children who have already received PCV7.

Dr. Camel's Conclusion

This research, like a well-worn path through the desert, provides a clear roadmap for effectively vaccinating children against pneumococcal infections. PCV13 offers a safe and effective way to complete the vaccination series in children who have already received PCV7, further strengthening their immunity and protecting them from these dangerous desert storms.

Date :
  1. Date Completed 2013-07-26
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

23306363

DOI: Digital Object Identifier

10.1016/j.vaccine.2012.12.066

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.